Search - tctmd.com

Displaying 1 - 20 of 119

Sort: Relevancy | Date

Presentation TCT 2025

Cerebral Embolic Protection Devices for Stroke Prevention: Is there Still a Role?

Presenter: Grant William Reed

October 28, 2025

Presentation TCT 2025

TCT 317: Impact of Very Severe Aortic Stenosis on Periprocedural Stroke Risk After Transcatheter Aortic Valve Replacement

Presenter: Jung-Joon Cha

October 26, 2025

Presentation TCT 2025

TCT 319: Short -Term Clinical Effect of Cerebral Embolic Protection Device Following Transcatheter Aortic-Valve Replacement in Korea Population: The Sentinel Registry (Sentinel)

Presenter: Han Su Park

October 26, 2025

Presentation TCT 2025

TCT 318: Stroke after TAVR - Impact on Clinical Outcome and Patient Reported Quality of Life (QoL): The Michigan Structural Heart Consortium (MISHC) Experience

Presenter: P. Michael Grossman

October 26, 2025

Presentation TCT 2025

TCT 322: Routine Use of Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials

Presenter: Hasan Ilyas

October 26, 2025

Presentation TCT 2025

TCT 321: Cerebral Embolic Protection Devices in Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials

Presenter: Mostafa Ali

October 26, 2025

Presentation TCT 2025

TCT 1455: When MAC Attacks: Stroke-Driven Discovery and Percutaneous Removal of a Mobile Mitral Annular Mass via Transseptal AngioVac With Cerebral Protection

Presenter: Huseyin Emre Arman

October 26, 2025

Presentation TCT 2025

TCT 21: Utility of Cerebral Embolic Protection in Transcaval Transcatheter Aortic Valve Replacement

Presenter: Victoria Coombe

October 25, 2025

Presentation TCT 2025

TCT 227: Routine Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials

Presenter: Mahmoud Ismayl

October 25, 2025

Presentation TCT 2025

TCT 230: Clinical Efficacy of Cerebral Embolism Protection Devices During Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-analysis of RCTs with Recent Evidence from PROTECT-TAVI

Presenter: Hasan Munshi

October 25, 2025

Presentation TCT 2024

TCT 846: Association of Cerebral Embolic Protection Device Use With Disabling Stroke After Transcatheter Aortic Valve Replacement: Insights From the National Inpatient Sample

Presenter: Jerry Lipinski

October 30, 2024

Presentation TCT 2024

TCT 316: Transradial/Brachial Carotid Artery Stenting With Proximal Cerebral Protection: A Feasible, Safe, and Effective First Line Strategy in 147 Consecutive Patients

Presenter: Piero Montorsi

October 29, 2024

Presentation TCT 2024

Cerebral Embolic Protection in the US Cohort of the PROTECTED TAVR Trial

Presenter: Samir Kapadia

October 29, 2024

Presentation TCT 2024

Case: Evolving Stroke After TAVR

Presenter: Jason Bloom

October 28, 2024

Presentation TCT 2024

Incidence, Diagnosis, and Management of Evolving Strokes After TAVR

Presenter: Julia Seeger

October 28, 2024

Presentation TCT 2024

A Sensible Approach to CEP for TAVR: From Clinical Trials to Clinical Practices

Presenter: Aakriti Gupta

October 28, 2024

Presentation TCT 2024

The Role of Cerebral Embolic Protection in TAVR

Presenter: Samir Kapadia

October 28, 2024

Presentation TCT 2024

TCT 151: First-in-Human Study of Novel Cerebral Protection in TAVR: An Alternative to Filter-Based Protection

Presenter: Frederick Funke

October 28, 2024

Presentation TCT 2024

Short- and Long-Term Effect of Cerebral Embolic Protection Device on New Brain Lesions Following Transcatheter Aortic-Valve Replacement: The Sentinel Registry (Sentinel)

Presenter: Han Su Park

October 27, 2024

Presentation TCT 2023

Counterpoint: The Evidence Simply Doesn’t Support Cerebral Protection, and Who’s Going to Pay for it Anyway?

Presenter: Suzanne Baron

October 26, 2023

Advertisement

Cerebral Embolic Protection Devices for Stroke Prevention: Is there Still a Role?

TCT 317: Impact of Very Severe Aortic Stenosis on Periprocedural Stroke Risk After Transcatheter Aortic Valve Replacement

TCT 319: Short -Term Clinical Effect of Cerebral Embolic Protection Device Following Transcatheter Aortic-Valve Replacement in Korea Population: The Sentinel Registry (Sentinel)

TCT 318: Stroke after TAVR - Impact on Clinical Outcome and Patient Reported Quality of Life (QoL): The Michigan Structural Heart Consortium (MISHC) Experience

TCT 322: Routine Use of Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials

TCT 321: Cerebral Embolic Protection Devices in Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials

TCT 1455: When MAC Attacks: Stroke-Driven Discovery and Percutaneous Removal of a Mobile Mitral Annular Mass via Transseptal AngioVac With Cerebral Protection

TCT 21: Utility of Cerebral Embolic Protection in Transcaval Transcatheter Aortic Valve Replacement

TCT 227: Routine Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials

TCT 230: Clinical Efficacy of Cerebral Embolism Protection Devices During Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-analysis of RCTs with Recent Evidence from PROTECT-TAVI

TCT 846: Association of Cerebral Embolic Protection Device Use With Disabling Stroke After Transcatheter Aortic Valve Replacement: Insights From the National Inpatient Sample

TCT 316: Transradial/Brachial Carotid Artery Stenting With Proximal Cerebral Protection: A Feasible, Safe, and Effective First Line Strategy in 147 Consecutive Patients

Cerebral Embolic Protection in the US Cohort of the PROTECTED TAVR Trial

Case: Evolving Stroke After TAVR

Incidence, Diagnosis, and Management of Evolving Strokes After TAVR

A Sensible Approach to CEP for TAVR: From Clinical Trials to Clinical Practices

The Role of Cerebral Embolic Protection in TAVR

TCT 151: First-in-Human Study of Novel Cerebral Protection in TAVR: An Alternative to Filter-Based Protection

Short- and Long-Term Effect of Cerebral Embolic Protection Device on New Brain Lesions Following Transcatheter Aortic-Valve Replacement: The Sentinel Registry (Sentinel)

Counterpoint: The Evidence Simply Doesn’t Support Cerebral Protection, and Who’s Going to Pay for it Anyway?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content